Merck & Co., Inc. operates as a global health care company delivering innovative health solutions through its prescription medicines, including biologic therapies, vaccines, and animal health products. The company’s operations are managed on a product basis, encompassing two operating segments: pharmaceutical and animal health. Merck's capital allocation priorities include making investments in its business to drive near- and long-term growth, supporting commercial opportunities, and addressing important unmet medical needs. The company continues to execute strategic business development opportunities to augment its robust internal pipeline with compelling external science. In 2022, Merck's results reflected sustained strong demand for its innovative product portfolio, enabled by strong operational and commercial execution, and progress in its pipeline across therapeutic areas. The company’s financial performance is influenced by its ability to mobilize and deploy IT-based resources in combination with leveraging the value of other resources and capabilities. Merck has made significant investments in research and development, reflecting higher clinical development spending particularly in oncology, cardiovascular, infectious diseases, and vaccines. The company’s strategic decisions are guided by the need to adapt to market dynamics and competitive actions, ensuring operational efficiency and effectiveness in its business processes. Merck's commitment to innovation is evident in its collaborations and licensing agreements, which aim to enhance its technology portfolio and capabilities in drug development. The company actively monitors the landscape for growth opportunities that meet its strategic criteria, focusing on partnerships that can enhance its research capabilities and market responsiveness. Merck's investments in digital technologies and infrastructure are designed to support its operational flexibility and enhance its information management capabilities, ensuring timely and accurate data provision to support decision-making processes. The company’s strategic resource allocation is aimed at optimizing its operational capabilities and enhancing its market-based performance. Merck's focus on digital transformation and IT deployment is integral to its business strategy, enabling the company to respond effectively to changing consumer demands and market conditions. The company’s organizational capabilities are enhanced through continuous investment in technology management and process optimization, which are critical for maintaining competitive advantage and achieving performance excellence. Merck's governance practices ensure that its IT capabilities align with its organizational goals, facilitating effective resource management and operational integration across its business segments. The company remains committed to leveraging its IT resources to support business innovation and transformation, ultimately driving value creation and enhancing its overall firm performance.